Immorna Earns FDA Approval for Phase I/II Clinical Trial of Self-Replicating RNA Cancer Therapy
Immorna (Hangzhou) Biotechnology, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has...
Immorna Biotechnology
Immorna Enrolls First Patient in Phase I Study of JCXH-211 for Malignant Tumors
Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of...
Immorna Closes Series A+ and A++ Rounds Near $100M for mRNA Development
Immorna (Hangzhou) Biotechnology Co., Ltd has announced the successful closure of Series A+ and A++...
Immorna’s JCXH-221 mRNA Vaccine Cleared by FDA for Phase I/II Study
Immorna (Hangzhou) Biotechnology Co., Ltd has announced that the US FDA has cleared its investigational...